Biocon Biologics receives positive CHMP opinions for denosumab biosimilars Vevzuo and Denosumab BBL Read more
Biocon Biologics announces positive results from Phase 3 Study of Yesintek biosimilar to Ustekinumab for chronic plaque psoriasis Read more